Medicare Part D May Lose Long-Term Luster For Pharma
Executive Summary
The Medicare drug benefit's positive effect on the pharmaceutical business could be short-lived, Wharton Business School Senior Fellow Stan Bernard suggested at the Pharmaceutical Marketing Congress in Philadelphia